tldrdailynews.com logo
Tag

Obesity Drugs

All articles tagged with #obesity drugs

Amylin and Triple-Agonist Trials Signal Next Wave in Obesity Treatment
health-and-science11 days ago

Amylin and Triple-Agonist Trials Signal Next Wave in Obesity Treatment

Eli Lilly and Novo Nordisk are advancing next-generation obesity treatments targeting the amylin pathway and multiple hormone receptors. Lilly’s Phase 2 trial showed its amylin drug eloralintide, combined with tirzepatide, achieved 23.3% weight loss, though side effects caused higher discontinuation rates. Meanwhile, Lilly’s triple-agonist retatrutide reached a Phase 3 milestone, with 12mg doses yielding 18.8% weight loss and improved metabolic markers in diabetic patients. Novo is preparing to launch its amylin-based CagriSema next year. These developments aim to address patients who do not respond adequately to current GLP-1 therapies, expanding treatment options through multi-pathway approaches.

via CNBC|
#amylin#eli-lilly#health-and-science
Lilly’s amylin-tirzepatide combo and retatrutide set new benchmarks for weight loss
health13 days ago

Lilly’s amylin-tirzepatide combo and retatrutide set new benchmarks for weight loss

Eli Lilly has advanced two major obesity treatments: a new amylin-tirzepatide combination and the triple-agonist retatrutide. The combination therapy achieved up to 23.3% weight loss in a Phase 2 trial, while retatrutide reached up to 25% weight loss in Phase 3 trials for obesity and 23% for Type 2 diabetes. Both drugs target multiple gut hormones to enhance satiety and metabolic effects, positioning them as potential alternatives to existing GLP-1 therapies. Lilly plans to file for retatrutide approval early next year and advance the combination therapy to Phase 3 trials by late 2026.

via Endpoints News|
#eli-lilly#eloralintide#glp-1
Lilly's amylin-tirzepatide combo hits 23% weight loss in Phase 2 trial
health-and-science13 days ago

Lilly's amylin-tirzepatide combo hits 23% weight loss in Phase 2 trial

Eli Lilly reported that its experimental combination of the amylin-targeting drug eloralintide and its existing GLP-1/GIP drug tirzepatide produced superior weight loss in a mid-stage trial. Patients with obesity and Type 2 diabetes lost up to 23.3% of their body weight over 48 weeks, outperforming tirzepatide alone. While the results are promising, higher discontinuation rates due to side effects raised questions about tolerability. Lilly plans to advance the therapy to Phase 3 trials by the end of 2026.

via CNBC|
#amylin#clinical-trials#eli-lilly
Eli Lilly Breaks Ground on $6.5 Billion Houston Plant to Scale Foundayo Production
business22 days ago

Eli Lilly Breaks Ground on $6.5 Billion Houston Plant to Scale Foundayo Production

Eli Lilly has broken ground on a new 240-acre manufacturing facility in Houston, Texas, with a projected cost of $6.5 billion. The plant, expected to be operational by 2030, will primarily produce the active ingredients for the company's oral GLP-1 weight-loss drug, Foundayo. CEO Dave Ricks stated that one-third of new GLP-1 pill patients are now using Foundayo, with market share growing weekly. This expansion follows a broader $50 billion manufacturing investment since 2020 and coincides with rising demand for the drug, which generated $98 million in sales during its first quarter on the market.

via CNBC|
#business#eli-lilly#foundayo
Novo Acquires Three Non-Incretin Obesity Programs from Kallyope to Diversify Pipeline
biotech24 days ago

Novo Acquires Three Non-Incretin Obesity Programs from Kallyope to Diversify Pipeline

Novo Nordisk, now rebranding as Novo, has acquired three early-stage obesity drug programs from New York-based biotech Kallyope. The deals include a first-in-class peptide candidate, a small molecule follow-on, and a receptor agonist, all targeting non-incretin pathways distinct from GLP-1s. The lead candidate, K-554, is IND-ready and aims to regulate food intake through novel biology. This move expands Novo’s metabolic pipeline beyond its core incretin drugs, aligning with its recent strategic shift to diversify treatments for obesity.

via Fierce Biotech|
#biotech#drug-pipeline#glp-1-alternatives
Novo Nordisk drops 'Nordisk' to pivot toward speed in obesity drug race
business29 days ago

Novo Nordisk drops 'Nordisk' to pivot toward speed in obesity drug race

Novo Nordisk is rebranding to simply 'Novo' and overhauling its corporate culture to regain momentum against Eli Lilly in the competitive obesity and diabetes market. The move, centered on the slogan 'Lasting Health Starts Now,' aims to simplify branding and accelerate innovation, though the company faces significant market share losses and recent clinical trial setbacks.

via Fierce Pharma|
#business#eli-lilly#novo-nordisk
Novo Nordisk Drops 'Nordisk' in Major Rebrand to Combat Eli Lilly
businesshealthcare29 days ago

Novo Nordisk Drops 'Nordisk' in Major Rebrand to Combat Eli Lilly

Novo Nordisk is rebranding to simply 'Novo' and overhauling its corporate culture to regain market share lost to Eli Lilly. The Danish firm faces intense competition and investor pressure, with shares down 15% this year despite the success of its oral Wegovy. The new strategy, dubbed 'Lasting Health Starts Now,' emphasizes speed, clear priorities, and patient-centric innovation to compete in a rapidly shifting obesity drug market.

via CNBC|
#businesshealthcare#eli-lilly#mike-doustdar
Medicare Opens Obesity-Drug Access for Seniors, Yet Awareness Is Lagging
health3 months ago

Medicare Opens Obesity-Drug Access for Seniors, Yet Awareness Is Lagging

Medicare’s Bridge demonstration program will start covering obesity medications for eligible beneficiaries with a $50 monthly copay, starting July 1, expanding access to GLP-1 drugs like Wegovy and Zepbound; however, awareness among seniors is low, enrollment isn’t automatic and requires a prescription plus prior authorization, and public outreach is being scaled up after launch as CMS and drugmakers prepare for possible demand through 2027.

via CNBC|
#bridge-program#glp-1#health
GLP-1 obesity drugs show early signs of boosting testosterone and sperm quality
health3 months ago

GLP-1 obesity drugs show early signs of boosting testosterone and sperm quality

A preliminary synthesis of trials and health‑record data suggests GLP‑1 obesity drugs may raise testosterone and improve sperm quality in men with obesity, but findings are mixed and need confirmation: some studies show testosterone increases, others show no change; one trial found GLP‑1 boosted testosterone while TRT increased it more and reduced sperm quality; a Mayo Clinic analysis observed about a 30% testosterone rise with GLP‑1–type therapies. More robust trials are needed.

via Nature|
#fertility#glp-1#health
Next-gen obesity drug race tightens as pivotal readouts loom
business4 months ago

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|
#business#eli-lilly#glp-1
Wegovy Drive Lifts Novo Nordisk's 2026 Guidance
business5 months ago

Wegovy Drive Lifts Novo Nordisk's 2026 Guidance

Novo Nordisk raised its 2026 guidance after a strong Q1 powered by Wegovy, with U.S. Wegovy prescriptions around 1.3 million and Wegovy sales of 2.26 billion DKK; first-quarter sales rose 32% cc to 96.8 billion DKK and reported operating profit jumped 65%, though adjusted sales fell 4% and adjusted profit fell 6% excluding a $4.2 billion 340B-related adjustment. The company plans to launch Wegovy outside the U.S. in H2 2026, and the stock rose intraday but closed at a new five-year low amid competition in the GLP-1 weight-loss market.

via CNBC|
#business#earnings#glp-1